Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

* First global approval of a once-daily, orally administered, Complement Factor B inhibitor

* Approval based on robust efficacy and safety data from Haisco's broad completed clinical development program in PNH